Enanta Pharmaceuticals | ENTA - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Amgen USD 657M 4M 2026-03
Anika Therapeutics 179.39M 556.84M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 411M 21M 2026-03
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 167M 21M 2026-03
Halozyme Therapeutics USD 4.91M 615K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Immunic 197K 222K 2025-12
Incyte USD 569K 13K 2026-03
Insmed USD 20.6M 217K 2025-12
Ionis Pharmaceuticals USD 17M 1000K 2026-03
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Ligand Pharmaceuticals USD 910K 243K 2025-09
Merck USD 479M 67M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 343M 39M 2026-03
Novavax USD 5.82M 342K 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Vertex Pharmaceuticals USD 3.3M 0 2025-12